The Peru Gazette

Prohibits Sale of Kratom to Individuals Under the Age of 21, Imposes Civil Penalties for Violations and Requires Product Warning Label Requirements 

NYS News Release of Dec. 22, 2025 – Governor Kathy Hochul today signed two pieces of landmark legislation to protect New Yorkers from the harmful effects of kratom, a commercially available herbal product sold for recreational use. This comes amid a rise in concerns about the link to potential health risks. Legislation S4552A/A2340A amends public health law to prohibit the sale of kratom products to individuals under 21 years of age. Legislation S8285/A5852A requires any kratom product being manufactured, distributed or sold in New York State to include a consumer warning label. 

“Kratom is a commercial substance that is commonly labeled an “all-natural herb”, leading people to believe it’s completely safe — but the reality is it can be extremely dangerous and unfortunately, in some cases, lethal,” Governor Hochul said. “No parent in New York should have to endure the loss of a child to a substance simply because they didn’t know what was in it. This legislation ensures transparency and strengthens our public health laws so that information about the ingredients and potential harmful risks associated with kratom are clear.”  

Legislation S4552A/A2340A will prohibit sales of kratom to persons under the age of 21. Under this legislation, anyone selling kratom to individuals under 21 years of age can face a fine of up to $500 for each offense.  

Legislation S8285/A5852A will require any kratom product to include a full list of ingredients as well as a consumer warning that the product may be addictive and may interact with certain medications, drugs and controlled substances. 

Kratom is an herb from Southeast Asia that may be used for its stimulant and analgesic, pain relief, effects. The substance is often taken as an energy booster, mood lifter, pain reliever or recreationally. Some consumers also report using kratom to relieve symptoms of withdrawal from opioids.  

While kratom itself is not an opioid, when taken in larger quantities, it can act in a way similar to other opioids, leading to tolerance, physical dependence and withdrawal symptoms. In some rare cases, deaths have been associated with kratom use, though in these cases kratom was usually used in combination with other substances, including fentanyl, other synthetic opioids, benzodiazepines, stimulants, alcohol, anti-convulsants and other medications.  

A minor natural component of kratom, 7-hydroxymitragynine (7-OH), can have a strong opioid effect when in concentrated form. Manufacturers have made synthetic 7-OH (which may be sold as 7-OH or added to kratom plant products) in substantially higher quantities than would be found in unadulterated kratom. Research about 7-OH and its potential association with dependence or overdose is ongoing. The New York State Department of Health began to specifically monitor 7-OH in June 2025.